Analysis of p540+ tetramer binding to circulating CD8+ T cells in HLA-A2+ cancer patients
Patient no. . | Tetramer-positive CD8+ T cells, % . | PSA, ng/mL . |
|---|---|---|
| 1 | 0.36 | 12.7 |
| 2 | 0.32 | 20.8 |
| 3 | 0.4 | 7.5 |
| 6 | 1.4 | 0 |
| 7 | 0 | 6.1 |
| 8 | 0.19 | 7 |
| 9 | 0.28 | 5.6 |
| 11 | 0.4 | 35 |
| 12 | 0.11 | 21 |
| 13 | 0.7 | 9.7 |
| 14 | 0.7 | 16 |
| 15 | 0.35 | 4.9 |
| 17 | 0.4 | 10 |
| 18 | 0.4 | 18 |
| 19 | 0.18 | — |
| 20 | 0.22 | — |
| 21 | 0 | — |
| 23 | 0.25 | — |
| 24 | 0.36 | — |
| 25 | 0.31 | — |
| 26 | 0.1 | — |
| 27 | 0.37 | — |
Patient no. . | Tetramer-positive CD8+ T cells, % . | PSA, ng/mL . |
|---|---|---|
| 1 | 0.36 | 12.7 |
| 2 | 0.32 | 20.8 |
| 3 | 0.4 | 7.5 |
| 6 | 1.4 | 0 |
| 7 | 0 | 6.1 |
| 8 | 0.19 | 7 |
| 9 | 0.28 | 5.6 |
| 11 | 0.4 | 35 |
| 12 | 0.11 | 21 |
| 13 | 0.7 | 9.7 |
| 14 | 0.7 | 16 |
| 15 | 0.35 | 4.9 |
| 17 | 0.4 | 10 |
| 18 | 0.4 | 18 |
| 19 | 0.18 | — |
| 20 | 0.22 | — |
| 21 | 0 | — |
| 23 | 0.25 | — |
| 24 | 0.36 | — |
| 25 | 0.31 | — |
| 26 | 0.1 | — |
| 27 | 0.37 | — |
— indicates patients not affected with prostate cancer.